Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

APPY 0.530 -0.018 (-3.21%)
price chart
Venaxis, Inc. to Present at Biotech Showcase™ 2015
6, 2015 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, and young ...
Related articles »  
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Venaxis, Inc. (APPY) Files Response with FDA Following Additional Information ...
Venaxis, Inc. (Nasdaq: APPY) announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission.
Related articles »  
Form 8-K Venaxis, Inc. For: Apr 07
These forward-looking statements are qualified by the cautionary statements contained in Venaxis' news releases and SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2014, which Venaxis filed on March 30, 2015.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces ...
NEW YORK, Jan. 29, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Venaxis, Inc. ("Venaxis" or the "Company") (NasdaqCM: APPY -News).
INVESTOR ALERT: Investigation of Venaxis, Inc. Announced by Glancy Binkow ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. (“Venaxis” or the “Company”) (NASDAQ:APPY) concerning possible violations of federal securities ...
Venaxis, Inc. (APPY) Presents APPY1 Test Data at ACEP14
Venaxis, Inc. (NASDAQ: APPY) announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ...  PR Newswire (press release)
Related articles »  
Venaxis Inc (NASDAQ:APPY) a Hold: Canaccord Genuity
In a research note issued to investors, Mark Massaro at Canaccord Genuity Reiterated their Hold rating on Venaxis Inc (NASDAQ:APPY).
Why Numerous Upside Scenarios Make Venaxis A Biotech To Buy (APPY)
With news being very light on names that I cover over the past few weeks, I wanted to initiate a new name today: Venaxis (NASDAQ:APPY).
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent ...
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Morning Market Losers  Benzinga